A Placebo-controlled Double-blind Parallel-Group Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
Overview
The purpose of this research is to find out if the study drug has a benefit on a person?s cognitive status via a series of specialized cognitive tests. The purpose of this research is also to find out if this study drug is safe and well-tolerated in people with early Alzheimer?s disease.
Description
The purpose of this research is to find out if the study drug has a benefit on a person?s cognitive status via a series of specialized cognitive tests. The purpose of this research is also to find out if this study drug is safe and well-tolerated in people with early Alzheimer?s disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 50 Years - 90 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1212010226
